About
Acrigen develops precision gene editing systems using proprietary CRISPR-Cas nuclease libraries and engineered anti-CRISPR proteins to enhance safety and efficacy in human therapeutic gene editing.
Explore Acrigen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.